top of page
REPOSE
REPOTRECTINIB IN ROS1-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVE BRAIN METASTASIS
CLINICAL TRIAL DETAILS
A PHASE II STUDY ASSESSING SAFETY AND EFFICACY OF REPOTRECTINIB IN ROS1-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVE BRAIN METASTASIS (REPOSE STUDY).
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
NSCLC BMs
20
II
Spain, Germany, Austria
Recruitment
TRIAL OVERVIEW
PRESS RELEASE
----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
----
TRIAL SITES
---
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page